An Analysis of Mechanisms for Cellular Uptake of miRNAs to Enhance Drug Delivery and Efficacy in Cancer Chemoresistance

Justine M. Grixti 1, Duncan Ayers 2,3,* and Philip J. R. Day 3

1 Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Biosciences Building, University of Liverpool, Liverpool L69 7ZB, UK; justine.grixti@liverpool.ac.uk
2 Centre for Molecular Medicine and Biobanking, University of Malta, Msida MSD 2080, Malta
3 Faculty of Biology, Medicine and Human Sciences, The University of Manchester, Manchester M1 7DN, UK; Philip.J.Day@manchester.ac.uk
* Correspondence: Duncan.Ayers@um.edu.mt

Abstract: Up until recently, it was believed that pharmaceutical drugs and their metabolites enter into the cell to gain access to their targets via simple diffusion across the hydrophobic lipid cellular membrane, at a rate which is based on their lipophilicity. An increasing amount of evidence indicates that the phospholipid bilayer-mediated drug diffusion is in fact negligible, and that drugs pass through cell membranes via proteinaceous membrane transporters or carriers which are normally used for the transportation of nutrients and intermediate metabolites. Drugs can be targeted to specific cells and tissues which express the relevant transporters, leading to the design of safe and efficacious treatments. Furthermore, transporter expression levels can be manipulated, systematically and in a high-throughput manner, allowing for considerable progress in determining which transporters are used by specific drugs. The ever-expanding field of miRNA therapeutics is not without its challenges, with the most notable one being the safe and effective delivery of the miRNA mimic/antagonist safely to the target cell cytoplasm for attaining the desired clinical outcome, particularly in miRNA-based cancer therapeutics, due to the poor efficiency of neo-vascular systems revolting around the tumour site, brought about by tumour-induced angiogenesis. This acquisition of resistance to several types of anticancer drugs can be as a result of an upregulation of efflux transporters expression, which egress drugs from cells, hence lowering drug efficacy, resulting in multidrug resistance. In this article, the latest available data on human microRNAs has been reviewed, together with the most recently described mechanisms for miRNA uptake in cells, for future therapeutic enhancements against cancer chemoresistance.

Keywords: miRNA; Drug Delivery; cancer chemoresistance; drug resistance; cell uptake

1. Transport Mechanisms: Introduction to Membrane Transporters

1.1. Role of Membrane Transporters in Cellular Uptake

Up until recently, it was believed, and in some text books it is still portrayed, that pharmaceutical drugs, and their metabolites, enter into the cell to gain access to their targets, via simple diffusion across the hydrophobic lipid cellular membrane, at a rate which is based on their lipophilicity [1–4]. An increasing amount of evidence indicates that the phospholipid bilayer-mediated drug diffusion is in fact negligible [1,5], and that drugs pass through cell membranes via proteinaceous membrane transporters or carriers which are normally used for the transportation of nutrients and intermediate metabolites, as shown in Figure 1 below [2,6–14].

Recognition that the flux of metabolites and pharmaceutical drugs into biological cells occurs through membrane transporters has important and beneficial implications. Drugs can be targeted to specific cells and tissues which express the relevant transporters, leading to the design of safe and efficacious treatments. Furthermore, transporter expression...
levels can be manipulated, systematically and in a high-throughput manner, allowing for considerable progress in determining which transporters are used by specific drugs [15].

Figure 1. Diagrams of the means by which a molecule, such as a drug, is transported across the cell membrane. (A) Diffusion through the phospholipid bilayer, at a rate which is dependent on the substrate’s lipophilicity, and (B) via membrane protein transporters which determine the drug’s flux and hence distribution and efficacy. (C) The eukaryotic cell membrane and its components, depicting the different ways of how substrates are transported intracellularly.

1.2. Membrane Transporters

A membrane transporter can be defined as an integral membrane protein [16] which regulates the transportation of physiological nucleosides and nucleobases for nucleic acid synthesis in the salvage pathways, metabolites and exogenous dietary products, as well as being the gatekeepers of transport of many drugs across the cell membrane [16–22]. The role of the eukaryotic cell membrane thus provides physical confines for all types of differentiated cells to conduct vital physiological processes, allowing only selected metabolites and/or key molecules to enter the cell cytoplasm, and similarly permits the efflux of specified endo-metabolites, ions, synthesised products, and ‘waste’ or toxic compounds into the extra cellular environment for systemic dispersion and/or removal.

Transporters comprise solute carriers, ion channels, water channels, and ATP-driven pumps [23]. Uniporters are integral membrane proteins that allow facilitated diffusion, binding to one molecule of substrate at a time, transporting it down its concentration gradient. Typical examples of uniporters include those associated with amino acid or glucose movement across the cell membrane. On the other hand, symporters and antiporters are involved in secondary active transport, where ATP, generated through an electrochemical gradient, is used to transport molecules against a concentration gradient. Symporters transport molecules in the same direction with respect to each other, in contrast to the antiporter transporter. Movement of ions across the plasma membrane is down their concentration gradient. This facilitated diffusion is coupled with active transport,
allowing for the other molecule(s) to be transported against their concentration gradient. Moreover, primary active transporters, transport substrates against their concentration gradient, deriving energy directly from the breakdown of ATP (see Figure 1).

In the context of cancer chemoresistance and miRNA influences on such tumour characteristics, the tumour cell membrane can play essential roles in allowing access to regulatory miRNAs present (either in free circulation or bound within exosomes) in the bloodstream. Considering that previous literature on this research niche is still in its infancy, the review describes possible manners in which the cell membrane-based compound uptake mechanisms act, for future clinical exploitation in developing more effective drug delivery of miRNA (or other non-coding RNA)-based therapeutics. However, for readers who are interested in identifying miRNAs that directly affect membrane transporter- and/or drug efflux transporter-related genes, the comprehensive review by Ayers and Vandesompele (2017) on this matter is freely available within the scientific literature, focusing solely on miRNAs and lncRNAs involved in cancer chemoresistance [24].

2. Transport Mechanisms across the Cell Membrane

Transport through transporters can be both passive and active. ‘Active’ transport occurs when the flux in or out of the cell at the expense of an energy source. ‘Passive’ transport is when not coupled by an energy source expenditure and simply flows from a region of high-concentration to a region of low-concentration. However, it is imperative to distinguish that passive transport does not mean that transportation through the cellular bilayer occurs via diffusion and is not carrier-mediated [4]. When a process is not energy coupled, thermodynamics terms this as passive in nature. However, this has nothing to do with its molecular mechanism.

As a result, transporters in humans are categorised into two major superfamilies, based on their thermodynamic properties and ATP coupling, namely the solute carrier (SLC) superfamily, which are generally influx transporters, and the ATP-binding cassette (ABC) superfamily, which are typically efflux transporters [11,21,22,25–27].

3. Chemoresistance

Primary treatment for both early and advanced tumours is achieved through chemotherapy. Unfortunately, drug resistance seriously limits the efficacy of conventional chemotherapeutics and novel biological agents, hence resulting in a major obstacle in the treatment of cancer. Drug resistance can be intrinsic in cases where the tumour is insensitive to therapeutic agents prior to any treatment. Otherwise, resistance is defined as acquired if the tumour develops resistance during the course of treatment [28]. This acquisition of resistance to several types of anticancer drugs can be as a result of an upregulation of efflux transporters expression, which eject drugs from cells, hence lowering drug efficacy, resulting in multidrug resistance [14,29]. Other mechanisms which contribute to drug resistance include insensitivity to apoptosis induced by drugs, increased repair of DNA damage, and recent data demonstrates that drug resistance might also be conferred to ncRNAs [28,30]. The next sections of this review article are, in fact, dedicated to the different transport mechanisms of ncRNAs, mainly miRNAs, and how these link to chemoresistant tumours.

4. Non-Coding RNAs

The term non-coding RNA (ncRNA) is commonly used to refer to RNA which does not encode a protein. However, this by no means implies that such RNA molecules serve zero functions. Recent advances in technology resulted in the revolutionisation of the molecular world and have shown that the majority of mammalian and genomes of other complex organisms is, in fact, transcribed into ncRNAs. Such RNA molecules form a hidden layer of internal signals which in turn control various levels of gene expression in physiology and development, including chromatin structure, epigenetic memory, transcription, RNA splicing, editing, translation, and turnover [31]. The miRNA family of non-coding RNAs is individually composed of an RNA duplex approximately 22 base pairs in length, with
one strand being complementary to specific target transcripts and ultimately leading to post-transcriptional repression of such transcripts [32–36]. The specific number of ncRNAs within the human genome is unknown. These are classified on the basis of their size; transcripts shorter than 200 nucleotides, including miRNAs, siRNAs, piRNAs, are referred to as ncRNAs. Transcripts with a length between 200 nt and 100 kb make up the second group, known as lncRNAs [31]. miRNAs is the class of ncRNAs which is most frequently studied. miRNAs are estimated to regulate ~30% of all protein-coding genes and are fundamental in shaping the global transcriptome of eukaryotes [37,38]. A more comprehensive overview of all ncRNA families can be found though the open access review by Micallef and Baron, published just recently [39].

**MicroRNA Functions and Their Clinical Importance**

Presently, there are over 2000 human miRNAs that have been identified, validated and catalogued following global efforts in novel miRNA discovery [40–42]. At the genomic levels, miRNAs are located in intronic areas of host genes or within intergenic regions [43]. Additionally, further research highlighted the fact that over 50% of all miRNAs expressed in humans fall within cancer-associated genomic regions or within fragile sites [44].

The initial stages of miRNA processing begin with transcription of the miRNA-bearing host gene within the cell nucleus into a pri-miRNA by the enzyme RNA polymerase II (Pol II) [45]. The pri-miRNA is essentially a long primary transcript, which is consequently targeted for cleavage by the nuclear enzyme Drosha into a precursor RNA (pre-miRNA), a stem-loop structured RNA approximately 60–70 base pairs in length [46]. The pre-miRNA is then transported out of the nucleus and into the cell cytoplasm by means of an Exportin-5/Ran-GTP enzyme complex [46]. Once the pre-miRNA is released into the cytoplasm, the RNase III enzyme Dicer binds onto its target pre-miRNA, resulting in the formation of a mature miRNA duplex (miRNA/miRNA*) of approximately 22 nucleotides in length but having two 3’ overhangs at both ends [47,48]. Finally, the mature miRNA duplex is then bound by the RNA-induced silencing complex (RISC), whereby the passenger mRNA* strand of the miRNA duplex is cleaved [49]. Consequently, the remaining miRNA strand of the mature miRNA acts as a guide for its bound RISC enzyme, with this strand being either totally or partially complementary to a unique sequence on the target mRNA [49].

Two possible modes of action exist by which the miRNA/RISC complex manages to inhibit translation of the target mRNA. If there is perfect complementarity between the miRNA and its target mRNA sequence, the latter is cleaved by means of the endonucleolytic properties of the Argonaute 2 (AGO2) domain present in RISC [50]. Alternatively, the miRNA binds to the 3’ untranslated region (UTR) of the target mRNA with imperfect complementarity on the 3’ UTR seed region (nucleotides #2-8), thus repressing translation of the target mRNA into its intended protein products [50].

The involvement of miRNA activity in shaping the development and severity of a vast spectrum of human disease conditions, including breast, lung, gastric, and liver cancers, HIV, influenza virus, multiple sclerosis, and type II diabetes [51], has undoubtedly affirmed their clinical importance [52–71]. This specific involvement via dysregulated miRNAs can enable their exploitation as reliable biomarkers for specific disease presence and/or clinical progress [72–81]. In addition, miRNA biomarkers can also qualify as novel drugs or drug targets for the potential development of novel miRNA-based therapeutics [82–91]. The mechanisms involved in enabling the physical uptake of circulating miRNAs was long thought to be based an ATP-independent diffusion through the individual cell membrane. However, emerging evidence in scientific literature relates the existence of exosomes that have the capacity to transport miRNAs through the systemic circulation to distal tissues.

5. Drug Delivery Issues in miRNA Therapeutics

The ever-expanding field of miRNA therapeutics is not without its challenges, with the most notable one being the safe and effective delivery of the miRNA mimic/antagonist
safely to the target cell cytoplasm for attaining the desired clinical outcome, particularly in miRNA-based cancer therapeutics, due to the poor efficiency of neo-vascular systems revolting around the tumour site, brought about by tumour-induced angiogenesis [92]. This challenge presents itself since the chemical composition of the vast majority of such novel therapeutic drugs is RNA-based, and therefore their direct administration in the patient bloodstream can lead to nuclease-directed elimination of the drug, the activation of the innate immune system mechanisms and/or immunotoxicity and neurotoxicity (particularly for miRNA mimic-based drugs) and also due to the sheer dose of the drug required for effective pharmacodynamic profiles [92–94]. Finally, even though the therapeutic miRNA payload can successfully reach the target tissues, there still remains the challenge of attaining sufficient intracellular delivery of the miRNAs (normally through endosomal formation) by effective endosomal escape mechanisms [92].

5.1. Current miRNA Drug Delivery Methods

5.1.1. Local Administration of miRNAs

The prospect of locally administering miRNA-based therapies directly into a solid tumour mass or immunoprivileged sites carries significant advantages, most notably the enhanced pharmacodynamic profile due to evasion of nuclease activity on the individual miRNA- oligonucleotide drug, together with reduced toxicity effects, since lower doses can effectively be administered for implementing the pharmacological effects required [92]. Several studies have successfully introduced miRNAs in a direct or topical manner for multiple conditions, including glioblastoma [95–98]. Such a method of administration can be highly effective for all conditions in which the site of pharmacological action can be accessed physically, including early stage cancer patients having a defined tumour mass. However, for other medical conditions and late stage/metastatic cancer contexts, local administration of miRNA-based therapies might not be the ideal therapeutic option.

5.1.2. Systemic Administration of miRNAs

The main advantage of administration of miRNA-based therapies in a systemic manner is to allow for the pharmacological action to affect ‘hard to reach’ target tissues afflicted by clinical conditions having miRNA dysregulated expression hallmarks. However, as described above, there are numerous challenges for such therapies to exert their intended functions efficiently and safely. Consequently, many bespoke miRNA-based drug delivery methods are currently in development to ensure safe passage of the oligonucleotides through the bloodstream and eventual target tissue, ultimately leading to cellular uptake of the oligonucleotides. Described briefly below are the current miRNA delivery methods being developed globally (see Table 1).

Table 1. Representation of differing modalities for systemic administration of miRNAs.

| Delivery Method                        | miRNA/s Involved                | Reference/s       |
|----------------------------------------|---------------------------------|-------------------|
| miRNA chemical modifications           |                                 |                   |
| 2’ OH- addition on ribose-ring          | Multiple miRNAs                | [99–101]          |
| Locked Nucleic Acids                   | miR-122                         | [102]             |
| Passenger Strand Alterations           | Multiple miRNAs                | [103]             |
| Viral-based delivery                   | Multiple miRNAs                | [104–120]         |
| Non-viral-based delivery               |                                 |                   |
| Polymer Nanoparticles (e.g., PEG; polyethylenimine) | Multiple miRNAs | [121–125]         |
| Inorganic Nanoparticles (e.g., Silica)  | miR-34a                        | [126–131]         |
| Lipid-based Vehicles                   | miR-34a; miR-29b                | [132,133]         |
| Folate—miRNA Conjugates               | miR-34a                        | [134]             |
| Exosomes                               | miR-21                         | [135]             |
Chemical Modifications on miRNA Structure

(a) 2′OH group modification

The ribose ring-based 2′ OH group is particularly exposed to nuclease activity and therefore is a challenge for the employment of chemically unmodified miRNA antagonists and mimics as a systemic-administered therapy [99]. Consequently, modification of the 2′ OH group (typically through 2′-O-methylation) is a highly effective means for preventing such modified oligonucleotides from nuclease degradation [99–101].

(b) Locked nucleic acids (LNAs)

Locked nucleic acids represent a conformational modification of the RNA backbone that can interact more avidly with the intended complimentary miRNA target sequence for which the miRNA antagonist/mimic has been designed [136]. This modification method is best represented through the successful development by Santaris [Denmark] of a LNA-antimiR for miR-122, capable of forming stable heteroduplexes with the targeted miRNA sequence [102]. The study also demonstrated that the effect of the LNA-antimiR for miR-122 was effective in reducing hepatitis C infection in vivo, in a dose dependent manner and no (murine) hepatotoxicity [102]. This novel technology has also been expanded to develop tiny LNAs with the capacity to bind avidly to 8-mer seed sequences common to entire families of miRNAs, such as the oncogenic miR-17~92 and miR-106b~25 clusters and have already demonstrated success in murine medulloblastoma studies [137–139].

(c) Passenger strand alterations and carrier vehicles

Modifications of the passenger strand apply only to miRNA mimic-based therapeutics, since there exists the presence of the RNA duplex. Such modifications can aid the degree of protection for the miRNA mimic from nuclease activity while in the bloodstream and also lead to reduced immunotoxicity effects, mainly due to Toll-Like Receptor-induced interferon systemic release [103]. In addition, such modifications do not affect the functionality and efficacy of the guide strand of the miRNA mimic [140,141].

Notwithstanding the efficacy of miRNA modifications in allowing increased success rates for the miRNA antagonist/mimic delivered safely to the site of pharmacological action, the efficiency in actual drug uptake by the target tissue component cells could still be enhanced through the use of carrier vehicles, such as biodegradable, biocompatible and non-toxic biopolymers including chitosan, cyclodextrins, poly-l-lysine, dextran, poly (lactic co-glycolic acid), polyglutamic acid, hyaluronic acid and gelatin [142]. These drug delivery systems have the added advantage (apart from protecting the drug during bloodstream passage) of having higher bonding affinity and interactions with the target tissue cell membrane, therefore enhancing the degree of drug uptake by the target cells [143].

Viral-Based Delivery Systems

The employment of viruses for drug payload protection and effective uptake by target tissues has long been evaluated for multiple drugs bearing a precariously fragile nature. This is in particular so for biologics-based drugs, as broadly described since the beginning of the gene therapy era in the early 1990s [144–147]. In the context of miRNA therapeutics, viral delivery systems are most apt for the transport of vectors coding for specific miRNA mimic/antagonist sequences, which also allows for a longer duration of action of the miRNA therapy within the target cells [104–120].

However, issues with risk of insertional mutagenesis of viral genomic sequences within patient tissues, ease of preparation and scalability of the viral delivery systems presently hinder such a drug delivery technology from entering the clinical setting on a widespread basis [148,149].
Non-Viral-Based Delivery Systems

(a) Polymer nanoparticles

The utilisation of polymer-based nanoparticles for enabling the delivery of a spectrum of drugs, including miRNAs, is becoming evermore commonplace with versatile and non-immunogenic polymers such as polyethylenimine and polyethylene glycol being utilised as nanoparticle backbones [121–125]. Typical advantages of the use of polymers for nanoparticle drug delivery systems include a highly flexible drug release kinetic profile on response to acid exposure [93].

(b) Inorganic nanoparticles

The use of non-polymer and non-immunogenic materials for the development of nanoparticles capable of drug delivery (including miRNAs) has also demonstrated considerable success.

One of the mainstay inorganic compounds employed for such drug delivery purposes is silica [126–131]. The study carried out by Stallings and colleagues was successful in utilising silica nanoparticles for the delivery of miR-34a in neuroblastoma murine tumour xenograft models [129].

The study performed by Yu and colleagues illustrated the efficiency of the utilisation other suitable inorganic materials, such as biodegradable bioactive glass nanoparticles, for the successful delivery of miRNAs [150]. The results of this study also highlighted the improved loading capacity of such glass nanoparticles compared to other inorganic compound-based nanoparticles such as mesoporous silica nanoparticles [150].

(c) Lipid-based vehicles

Undoubtedly, the efforts carried out by Mirna therapeutics [TX, USA] earlier in this decade have led to clinical trials for the first ever miRNA replacement therapy for lung cancer treatment [132]. The study conducted by Wiggins and colleagues demonstrated that miR-34a was downregulation in non-small-cell lung cancer (NSCLC) patients and reverting the expression level through artificially induced upregulation inhibited multiple NSCLC cell line growth [132]. The study also successfully demonstrated the effect of miR-34a upregulation within in vivo tumour xenograft models for NSCLC, utilising a neutral, lipid emulsion-based delivery vehicle [132].

This miRNA delivery method was also employed in the study conducted by Wu and colleagues, studying the possible use of miR-29b as a separate miRNA replacement therapy for NSCLC [133]. The variation employed for this specific miRNA delivery mechanism was namely the use of cationic lipoplexes rather than neutral lipid emulsions [133]. The utilisation of such a cationic lipid (1,2-di-O-octadecenyl-3-trimethylammonium propane—DOTMA, as chloride salt) enhances the degree of interplay between the negatively charged target cell membrane and the DOTMA-induced positively charged lipocomplex surface, resulting in higher transfection efficacy and uniformity of miRNA uptake by the target cells [133]. Cholesterol was also utilised for the miRNA delivery vehicle due to its protective role against the miRNA mimic oligonucleotide degradation and since it also aids interaction between the target cell membrane and the miRNA-bearing lipoplexes, resulting in enhanced miRNA uptake by the target cells [133]. It is also noteworthy to mention the use of lipid nanoparticle-based measures can be of utility in delivering miRNA-based therapeutics in the near future [151–153].

(d) Folate–miRNA conjugates

Interestingly, the study carried out by Orellana and colleagues in 2017 adopted the use of folamiRs—namely, the direct attachment of miRNAs to folate which enhances the possibility of such miRNA conjugates to be taken up by (tumour) cells overexpressing folate receptors [134]. This study successfully introduced FolamiR-34a (folate–miR-34a conjugate) by triple-negative breast cancer cells at both in vitro and in vivo levels [134].
Exosomes

Recent evidence has demonstrated the existence of exosomes that are essentially minute membrane vesicles carrying a myriad of intracellular compounds and proteins [154]. Such exosomes can also be secreted into the systemic circulation for eventual downstream uptake by cells from distal tissues, allowing for remote effector function from the exosomal host cells on release of the key compounds and/or proteins released upon exosome uptake by distal cells [155–157]. The actual uptake mechanism of such exosomes can either occur through receptor-mediated endocytosis, with consequential release of the hydrophilic exosomal contents, or through direct fusion of the exosome with the target cell membrane, releasing contents directly into the cytoplasm of the target cell [158–160].

The effector functions of exosomes can also be applied for gene regulatory purposes due to the efficient transfer of miRNAs withing exosomes. Zheng and colleagues very recently identified the key roles played by exosomal transfer of tumour-associated macrophage-derived miR-21 for the development of cisplatin resistance by gastric carcinoma cells [135]. In addition, multiple evidence within the scientific literature exists that describes the effects of exosomal transfer of miRNAs that induce tumourigenicity and other key phenotypic characteristics of tumours, particularly between the bone marrow adipose and multiple myeloma cell populations [161].

Although still in its infancy, the existence of exosomal transfer of miRNAs for tumour development can be exploited by artificial development of exosomes carrying miRNA antagonists/mimics for deployment and cellular uptake within the same distal tissues.

6. Conclusions and Perspectives

The clinical importance of optimally functioning molecular transport mechanisms within the cell, regardless of the tissue type, can never be underestimated. This statement in favour of the PDIN hypothesis is reflected by the myriad of medical conditions, a handful of which are described below, that arise or are aggravated due to improper/lack of effectiveness in channelling specific molecular players across the cell membrane of the afflicted tissue structures.

The utility of copper as an essential molecular component for enabling effective cellular-level physiological functions, such as angiogenesis, wound healing and shielding from reactive oxidative stress, essentially depends on the degree of presence of human copper transporter 1 (hCTR1) bound onto the cell membrane [162–164]. Consequently, altered hCTR1 protein expression levels can be detrimental to the cell physiology. In addition, the hCTR1 can also aid the uptake of platinum through the cell membrane, which has been demonstrated to affect the platinum chemoresistance levels of muscle-invasive bladder cancer patients due to low uptake of the metal when hCTR1 cell membrane presence is low [165].

The transport of cholesterol across the cell membrane is handled by the transmembrane efflux pump known as Niemann–Pick disease type 1 (NPC1) [166]. Functional issues relating to NPC1 ultimately lead to the accumulation of cholesterol, together with cytotoxic agents such as daunorubicin, in the affected cells’ endosomal/lysosomal infrastructure within the cell cytoplasm [166]. Eventually, such efflux pump dysfunction directly contributes to the development of Niemann–Pick disease and the emergence of cancer chemoresistance properties by the affected tissues [166]. One recent study has found miR-33 to have regulatory roles on NPC1 [167].

It is hoped that further evolution of such technologies, all pertaining to the study and analyses of drug uptake mechanisms, could lead us to further evidence for this matter. Eventually, this gain in knowledge can be employed for the development of more effective drugs having much improved pharmacodynamic profiles and consequently allowing such novel drugs to achieve clinically therapeutic levels at much lower doses in the near future through maximised efficiency of cellular uptake mechanisms.
**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Kell, D.B. What Would Be the Observable Consequences If Phospholipid Bilayer Diffusion of Drugs into Cells Is Negligible? *Trends Pharmacol. Sci.* **2015**, *36*, 15–21. [CrossRef] [PubMed]

2. Dobson, P.D.; Kell, D.B. Carrier-Mediated Cellular Uptake of Pharmaceutical Drugs: An Exception or the Rule? *Nat. Rev. Drug Discov.* **2008**, *7*, 205–220. [CrossRef] [PubMed]

3. Lanthaler, K.; Bilisland, E.; Dobson, P.D.; Moss, H.J.; Pir, P.; Kell, D.B.; Oliver, S.G. Genome-Wide Assessment of the Carriers Involved in the Cellular Uptake of Drugs: A Model System in Yeast. *BMC Biol.* **2011**, *9*, 70. [CrossRef]

4. Kell, D.B.; Oliver, S.G. How Drugs Get into Cells: Tested and Testable Predictions to Help Discriminate between Transporter-Mediated Uptake and Lipoidal Bilayer Diffusion. *Front. Pharmacol.* **2014**, *5*, 231. [CrossRef]

5. Swainston, N.; Mendes, P.; Kell, D.B. An Analysis of a “community-Driven” Reconstruction of the Human Metabolic Network. *Metabolomics* **2013**, *9*, 757–764. [CrossRef]

6. Al-Awqati, Q. One Hundred Years of Membrane Permeability: Does Overton Still Rule? *Nat. Cell Biol.* **1999**, *1*, E201–E202. [CrossRef]

7. Dobson, P.D.; Lanthaler, K.; Oliver, S.G.; Kell, D.B. Implications of the Dominant Role of Transporters in Drug Uptake by Cells. *Curr. Top. Med. Chem.* **2009**, *9*, 163–181. [CrossRef]

8. Burckhardt, G.; Burckhardt, B.C. In Vitro and in Vivo Evidence of the Importance of Organic Anion Transporters (OATs) in Drug Therapy. *Handb. Exp. Pharmacol.* **2011**, 29–104. [CrossRef]

9. Kell, D.B.; Dobson, P.D.; Oliver, S.G. Pharmaceutical Drug Transport: The Issues and the Implications That It Is Essentially Carrier-Mediated Only. *Drug Discov. Today* **2011**, *16*, 704–714. [CrossRef] [PubMed]

10. DeGorter, M.K.; Xia, C.Q.; Yang, J.J.; Kim, R.B. Drug Transporters in Drug Efficacy and Toxicity. *Annu. Rev. Pharmacol. Toxicol.* **2012**, *52*, 249–273. [CrossRef] [PubMed]

11. Giacomini, K.M.; Huang, S.-M. Transporters in Drug Development and Clinical Pharmacology. *Clin. Pharmacol. Ther.* **2013**, *94*, 3–9. [CrossRef]

12. Kell, D.B.; Dobson, P.D.; Bilisland, E.; Oliver, S.G. The Promiscuous Binding of Pharmaceutical Drugs and Their Transporter-Mediated Uptake into Cells: What We (Need to) Know and How We Can Do So. *Drug Discov. Today* **2013**, *18*, 218–239. [CrossRef] [PubMed]

13. Kell, D.B.; Goodacre, R. Metabolomics and Systems Pharmacology: Why and How to Model the Human Metabolic Network for Drug Discovery. *Drug Discov. Today* **2014**, *19*, 171–179. [CrossRef] [PubMed]

14. Grixti, J.M.; O’Hagan, S.; Day, P.J.; Kell, D.B. Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. *Front. Pharmacol.* **2017**, *8*, 155. [CrossRef] [PubMed]

15. Kell, D.B. Implications of Endogenous Roles of Transporters for Drug Discovery: Hitchhiking and Metabolite-Likeness. *Nat. Rev. Drug Discov.* **2016**, *15*, 143. [CrossRef] [PubMed]

16. Marvi, M.; Rose, J.B.; Bang, A.; Moon, B.C.; Pozeg, Z.; Ibrahim, M.; Peniston, C.; Coe, I.R. Nucleoside Transporter Expression Profiles in Human Cardiac Tissue Show Striking Individual Variability with Overall Predominance of HENT1. *J. Eur. J. Pharm. Sci.* **2010**, *41*, 685–691. [CrossRef]

17. Kong, W.; Engel, K.; Wang, J. Mammalian Nucleoside Transporters. *Curr. Drug Metab.* **2004**, *5*, 63–84. [CrossRef]

18. Podgorska, M.; Kocbuch, K.; Pawelczyk, T. Recent Advances in Studies on Biochemical and Structural Properties of Equilibrative and Concentrative Nucleoside Transporters. *Acta Biochim. Pol.* **2005**, *52*, 749–758. [CrossRef]

19. Nakano, Y.; Tanno, S.; Koizumi, K.; Nishikawa, T.; Nakamura, K.; Minoguchi, M.; Izawa, T.; Mizukami, Y.; Okumura, T.; Kohgo, Y. Gemcitabine Chemoresistance and Molecular Markers Associated with Gemcitabine Transport and Metabolism in Human Pancreatic Cancer Cells. *Br. J. Cancer* **2007**, *96*, 457–463. [CrossRef]

20. Molina-Arcas, M.; Casado, F.J.; Pastor-Anglada, M. Nucleoside Transporter Proteins. *Curr. Vasc. Pharmacol.* **2009**, *7*, 426–434. [CrossRef]

21. Hediger, M.A.; Clémençon, B.; Burrier, R.E.; Bruford, E.A. The ABCs of Membrane Transporters in Health and Disease (SLC Series): Introduction. *Mol. Asp. Med.* **2013**, *34*, 95–107. [CrossRef]

22. Johnson, Z.L.; Lee, J.-H.; Lee, K.; Lee, M.; Kwon, D.-Y.; Hong, J.; Lee, S.-Y. Structural Basis of Nucleoside and Nucleoside Drug Selectivity by Concentrative Nucleoside Transporters. *Elife* **2014**, *3*, e03604. [CrossRef]

23. César-Razquin, A.; Snijder, B.; Frappier-Brinton, T.; Isserlin, R.; Gyimesi, G.; Bai, X.; Reithmeier, R.A.; Hepworth, D.; Hediger, M.A.; Edwards, A.M.; et al. A Call for Systematic Research on Solute Carriers. *Cell* **2015**, *162*, 478–487. [CrossRef]
24. Ayers, D.; Vandesompele, J. Influence of MicroRNAs and Long Non-Coding RNAs in Cancer Chemoresistance. *Genes* 2017, 8, 95. [CrossRef]

25. Ward, J.L.; Sherali, A.; Mo, Z.P.; Tse, C.M. Kinetic and Pharmacological Properties of Cloned Human Equilibrative Nucleoside Transporters, ENT1 and ENT2, Stably Expressed in Nucleoside Transporter-Deficient PK15 Cells. Ent2 Exhibits a Low Affinity for Guanosine and Cytidine but a High Affinity for Inosine. *J. Biol. Chem.* 2000, 275, 8375–8381. [CrossRef]

26. Hediger, M.A.; Romero, M.F.; Peng, J-B.; Rolfs, A.; Takanaga, H.; Brudoff, E.A. The ABCs of Solute Carriers: Physiological, Pathological and Therapeutic Implications of Human Membrane Transport Proteins. *Introduction*. *Pflugers Arch.* 2004, 447, 465–468. [CrossRef]

27. He, L.; Vasiliev, K.; Nebert, D.W. Analysis and Update of the Human Solute Carrier (SLC) Gene Superfamily. *Hum. Genom.* 2009, 3, 195–206. [CrossRef]

28. Corrêa, F.; Agnoletto, C.; Minotti, L.; Baldassari, F.; Volinia, S. The Network of Non-Coding RNAs in Cancer Drug Resistance. *Front. Oncol.* 2018, 8, 327. [CrossRef]

29. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug Resistance in Cancer: Role of ATP-Dependent Transporters. *Nat. Rev. Cancer* 2002, 2, 48–58. [CrossRef]

30. Fojo, T. Multiple Paths to a Drug Resistance Phenotype: Mutations, Translocations, Deletions and Amplification of Coding Genes or Promoter Regions, Epigenetic Changes and MicroRNAs. *Drug Resist. Updat.* 2007, 10, 59–67. [CrossRef]

31. Giri, J.M.; Ayers, D. Long Noncoding RNAs and Their Link to Cancer. *Noncoding RNA Res.* 2020, 5, 77–82. [CrossRef] [PubMed]

32. Ambros, V. MicroRNAs: Tiny Regulators with Great Potential. *Cell* 2001, 107, 823–826. [CrossRef]

33. Lai, E.C. Micro RNAs Are Complementary to 3’ UTR Sequence Motifs That Mediate Negative Post-Transcriptional Regulation. *Cell* 2003, 103, 363–366. [CrossRef]

34. Ke, X-S.; Liu, C-M.; Liu, D-P.; Liang, C-C. MicroRNAs: Key Participants in Gene Regulatory Networks. *Curr. Opin. Chem. Biol.* 2007, 3, 516–523. [CrossRef]

35. Bartel, D.P. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. *Cell* 2004, 116, 281–297. [CrossRef]

36. Doench, J.G.; Sharp, P.A. Specificity of MicroRNA Target Selection in Translational Repression. *Genes Dev.* 2004, 18, 504–511. [CrossRef]

37. Fatima, F.; Nawaz, M. Stem Cell-Derived Exosomes: Roles in Stromal Remodeling, Tumor Progression, and Cancer Immunotherapy. *Chin. J. Cancer* 2015, 34, 541–553. [CrossRef]

38. Grosshans, H.; Filipowicz, W. Proteomics Joins the Search for MicroRNA Targets. *Genes Dev.* 2008, 134, 560–562. [CrossRef]

39. Micallef, I.; Baron, B. The Mechanistic Roles of NcrRNAs in Promoting and Supporting Chemoresistance of Colorectal Cancer. *Noncoding RNA 2021*, 7, 24. [CrossRef]

40. Griffiths-Jones, S. MiRBase: The MicroRNA Sequence Database. *Methods Mol. Biol.* 2006, 342, 129–138. [CrossRef]

41. Griffiths-Jones, S.; Grocock, R.J.; van Dongen, S.; Bateman, A.; Enright, A.J. MiRBase: MicroRNA Sequences, Targets and Gene Nomenclature. *Nucleic Acids Res.* 2006, 34, D140–D144. [CrossRef]

42. Pang, K.C.; Stephen, S.; Dinger, M.E.; Engström, P.G.; Lenhard, B.; Mattick, J.S. RNAdb 2.0–an Expanded Database of Mammalian Non-Coding RNAs. *Nucleic Acids Res.* 2007, 35, D178–D182. [CrossRef]

43. Rodriguez, A.; Griffiths-Jones, S.; Ashurst, J.L.; Bradley, A. Identification of Mammalian MicroRNA Host Genes and Transcription Units. *Genome Res.* 2004, 14, 1902–1910. [CrossRef] [PubMed]

44. Sevignani, C.; Calin, G.A.; Siracusa, L.D.; Croce, C.M. Mammalian MicroRNAs: A Small World for Fine-Tuning Gene Expression. *Mamm. Genome* 2006, 17, 189–202. [CrossRef] [PubMed]

45. Davis, B.N.; Hata, A. Mechanisms of Control of MicroRNA Biogenesis. *J. Biochem.* 2010. [CrossRef]

46. Chhabra, R.; Dubey, R.; Saini, N. Cooperative and Individualistic Functions of the MicroRNAs in the MiR-23a~27a~24-2 Cluster and Its Implication in Human Diseases. *Mol. Cancer* 2010, 9, 232. [CrossRef] [PubMed]

47. Merritt, W.M.; Bar-Eli, M.; Sood, A.K. The Dicey Role of Dicer: Implications for RNAi Therapy. *Cancer Res.* 2010, 70, 2571–2574. [CrossRef]

48. Garofalo, M.; Croce, C.M. MicroRNAs: Master Regulators as Potential Therapeutics in Cancer. *Annu. Rev. Pharmacol. Toxicol.* 2010. [CrossRef]

49. Kwak, P.B.; Iwasaki, S.; Tomari, Y. Review Article: The MicroRNA Pathway and Cancer. *Cancer Sci.* 2010. [CrossRef]

50. Wu, L.; Belasco, J.G. Let Me Count the Ways: Mechanisms of Gene Regulation by MiRNAs and SiRNAs. *Mol. Cell* 2008, 29, 1–7. [CrossRef]

51. Li, H.; Huang, S.; Guo, C.; Guan, H.; Xiong, C. Cell-Free Seminal MRNA and MicroRNA Exist in Different Forms. *PLoS ONE* 2012, 7, e34566. [CrossRef]

52. Zang, H.; Wang, W.; Fan, S. The Role of MicroRNAs in Resistance to Targeted Treatments of Non-Small Cell Lung Cancer. *Cancer Chemother. Pharmacol.* 2016. [CrossRef]

53. Abdi, J.; Jian, H.; Chang, H. Role of Micro-RNAs in Drug Resistance of Multiple Myeloma. *Onctarget* 2016. [CrossRef] [PubMed]

54. Hu, Y.; Wang, H.; Chen, E.; Xu, Z.; Chen, B.; Lu, G. Candidate MicroRNAs as Biomarkers of Thyroid Carcinoma: A Systematic Review, Meta-Analysis, and Experimental Validation. *Cancer Med.* 2016. [CrossRef]

55. Tao, Z-Q.; Shi, A-M.; Li, R.; Wang, Y-Q.; Wang, X.; Zhao, J. Role of MicroRNA in Prostate Cancer Stem/Progenitor Cells Regulation. *Eur. Rev. Med. Pharmacol. Sci.* 2016, 20, 3040–3044. [PubMed]
56. Barreiro, E. The Role of MicroRNAs in COPD Muscle Dysfunction and Mass Loss: Implications on the Clinic. Expert Rev. Respir. Med. 2016, 1–12. [CrossRef] [PubMed]

57. Perdas, E.; Stawski, R.; Nowak, D.; Zubrzycka, M. The Role of MiRNA in Papillary Thyroid Cancer in the Context of MiRNA Let-7 Family. Int. J. Mol. Sci. 2016, 17, 909. [CrossRef]

58. Due, H.; Svendsen, P.; Bødker, J.S.; Schnitzius, A.; Bøsted, M.; Johnsen, H.E.; El-Galaly, T.C.; Roug, A.S.; Dybkær, K. MiR-155 as a Biomarker in B-Cell Malignancies. Biomedi. Res. Int. 2016, 2016, 9513037. [CrossRef]

59. Shea, A.; Harish, V.; Afzal, Z.; Chijioke, J.; Kedir, H.; Dusmatova, S.; Roy, A.; Ramalinga, M.; Harris, B.; Blancto, J.; et al. MicroRNAs in Glioblastoma Multiforme Pathogenesis and Therapeutics. Cancer Med. 2016, 5, 1917–1946. [CrossRef]

60. Ram Kumar, R.M.; Boro, A.; Fuchs, B. Involvement and Clinical Aspects of MicroRNA in Osteosarcoma. Int. J. Mol. Sci. 2016, 17, 877. [CrossRef]

61. Azizian, A.; Gruber, J.; Ghadimi, B.M.; Gaedcke, J. MicroRNA in Rectal Cancer. World J. Gastrointest. Oncol. 2016, 8, 416–426. [CrossRef]

62. Reddy, P.H.; Tonk, S.; Kumar, S.; Vijayan, M.; Kandimalla, R.; Kuruva, C.S.; Reddy, A.P. A Critical Evaluation of Neuroprotective and Neurodegenerative MiRNAs in Alzheimer’s Disease. Biochem. Biophys. Res. Commun. 2016. [CrossRef]

63. Li, H.-Y.; Zhao, X.; Liu, Y.-Z.; Meng, Z.; Wang, D.; Yang, F.; Shi, Q.-W. Plasma MicroRNA-126-5p Is Associated with the Complexity and Severity of Coronary Artery Disease in Patients with Stable Angina Pectoris. Cell. Physiol. Biochem. 2016, 39, 837–846. [CrossRef] [PubMed]

64. Ayers, D.; Mestdagh, P.; Van Maerken, T.; Vandesompele, J. Identification of MiRNAs Contributing to Neuroblastoma Chemoresistance. Comput. Struct. Biotechnol. J. 2015, 13, 307–319. [CrossRef]

65. Shi, D.-L.; Shi, G.-R.; Xie, J.; Du, X.-Z.; Yang, H. MicroRNA-27a Inhibits Cell Migration and Invasion of Fibroblast-Like Synoviocytes by Targeting Follistatin-Like Protein 1 in Rheumatoid Arthritis. Mol. Cells 2016. [CrossRef]

66. Vijayan, M.; Reddy, P.H. Peripheral Biomarkers of Stroke: Focus on Circulatory MicroRNAs. Biochim. Biophys. Acta 2016, 1862, 1984–1993. [CrossRef] [PubMed]

67. Liao, X.-J.; Mao, W.-M.; Wang, Q.; Yang, G.-G.; Wu, W.-J.; Shao, S.-X. MicroRNA-24 Inhibits Serotonin Reuptake Transporter Expression and Aggravates Irritable Bowel Syndrome. Biochem. Biophys. Res. Comm. 2016, 469, 288–293. [CrossRef] [PubMed]

68. Kim, R.Y.; Horvat, J.C.; Pinkerton, J.W.; Starkey, M.R.; Essilfie, A.T.; Mayall, J.R.; Nair, P.M.; Hansbro, N.G.; Jones, B.; Haw, T.J.; et al. MicroRNA-21 Drives Severe, Steroid-Insensitive Experimental Asthma by Amplifying Phosphoinositide 3-Kinase-Mediated Suppression of Histone Deacetylase 2. J. Allergy Clin. Immunol. 2016. [CrossRef]

69. Kichukova, T.M.; Popov, N.T.; Ivanov, H.Y.; Vachev, T.I. Circulating MicroRNAs as a Novel Class of Potential Diagnostic Biomarkers in Neuropsychiatric Disorders. Folia Med. 2015, 57, 159–172. [CrossRef] [PubMed]

70. Hsu, Y.-C.; Chang, P.-J.; Ho, C.; Huang, Y.-T.; Shih, Y.-H.; Wang, C.-J.; Lin, C.-L. Protective Effects of MiR-29a on Diabetic Glomerular Dysfunction by Modulation of DKK1/Wnt/β-Catenin Signaling. Sci. Rep. 2016, 6, 30575. [CrossRef] [PubMed]

71. Gurusuraj, A.; Naughton, M.E.; Scott, K.A.; O’Connor, R.M.; Moloney, G.; Clarke, G.; Dowling, J.; Walsh, A.; Ismail, F.; Shorten, G.; et al. MicroRNAs as Biomarkers for Major Depression: A Role for Let-7b and Let-7c. Transl. Psychiatry 2016, 6, e862. [CrossRef] [PubMed]

72. Matin, F.; Jeet, V.; Clements, J.A.; Yousef, G.M.; Batra, J. MicroRNA Theranostics in Prostate Cancer Precision Medicine. Clin. Chem. 2016. [CrossRef]

73. Ebrahimi, S.; Ghasemi, F.; Hassanian, S.M.; Shahidsales, S.; Mardani, R.; Akbarzade, H.; Parizadeh, S.M.R.; Gholamin, S.; Soleimani, A.; Ghayour-Mobarhan, M.; et al. Circulating MicroRNAs as Novel Potential Diagnostic and Prognosis Biomarkers in Pancreatic Cancer. Curr. Pharm. Des. 2016, 22, 6444–6450. [CrossRef]

74. Arabpour, M.; Mohammadparast, S.; Maftouh, M.; ShahidSales, S.; Moieni, S.; Akbarzade, H.; Mirhafez, S.R.; Parizadeh, S.M.R.; Hassanian, S.M.; Avan, A. Circulating MicroRNAs as Potential Diagnostic Biomarkers and Therapeutic Targets in Gastric Cancer: Current Status and Future Perspectives. Curr. Med. Chem. 2016, 23, 4135–4150. [CrossRef]

75. Giuffrida, P.; Pinzani, M.; Corazza, G.R.; Di Sabatino, A. Biomarkers of Intestinal Fibrosis—One Step towards Clinical Trials for Stricturetng Inflammatory Bowel Disease. United Eur. Gastroenterol. J. 2016, 4, 523–530. [CrossRef] [PubMed]

76. Sheikh, A.M.; Small, H.Y.; Currie, G.; Delles, C. Systematic Review of Micro-RNA Expression in Pre-Eclampsia Identifies a Number of Common Pathways Associated with the Disease. PLoS ONE 2016, 11, e0160808. [CrossRef] [PubMed]

77. Qi, X.; Zhu, H.; Liu, S.; Tao, G.; Jin, J.; Chu, H.; Wang, M.; Tong, N.; Gong, W.; Zhao, Q.; et al. Expression and Prognostic Value of MicroRNA-26a and MicroRNA-148a in Gastric Cancer. J. Gastroenterol. Hepatol. 2016. [CrossRef]

78. Bai, S.; Tian, B.; Li, A.; Yao, Q.; Zhang, G.; Li, F. MicroRNA-125b Promotes Tumor Growth and Suppresses Apoptosis by Targeting DRAM2 in Retinoblastoma. Eye 2016. [CrossRef]

79. Gao, X.; Wang, Y.; Zhao, H.; Wei, F.; Zhang, X.; Su, Y.; Wang, C.; Li, H.; Ren, X. Plasma MiR-324-3p and MiR-1285 as Diagnostic and Prognostic Biomarkers for Early Stage Lung Squamous Cell Carcinoma. Oncotarget 2016. [CrossRef]

80. Roy, R.; Singh, R.; Chattopadhyay, E.; Ray, A.; De Sarkar, N.; Aich, R.; Paul, R.R.; Pal, M.; Roy, B. MicroRNA and Target Gene Expression Based Clustering of Oral Cancer, Precancer and Normal Tissues. Gene 2016. [CrossRef]

81. Lin, Z.; Zhao, J.; Wang, X.; Zhu, X.; Gong, L. Overexpression of MicroRNA-497 Suppresses Cell Proliferation and Induces Apoptosis through Targeting Paired Box 2 in Human Ovarian Cancer. Oncol. Rep. 2016. [CrossRef]

82. Cui, X.; Li, Z.; Gao, J.; Gao, P.-J.; Ni, Y.-B.; Zhu, J.-Y. Elevated CXCL1 Increases Hepatocellular Carcinoma Aggressiveness and Is Inhibited by MicroRNA-200a. Oncotarget 2016. [CrossRef]
83. Ma, W.; Ma, C.-N.; Zhou, N.-N.; Li, X.-D.; Zhang, Y.-J. Up-Regulation of MiR-328-3p Sensitizes Non-Small Cell Lung Cancer to Radiotherapy. *Sci. Rep.* 2016, 6, 31651. [CrossRef] [PubMed]

84. Hong, L.; Sharp, T.; Khorsand, B.; Fischer, C.; Eliason, S.; Salem, A.; Akkouch, A.; Brogden, K.; Amendt, B.A. MicroRNA-200c Represses IL-6, IL-8, and CCL-5 Expression and Enhances Osteogenic Differentiation. *PloS ONE* 2016, 11, e0160915. [CrossRef] [PubMed]

85. Cabello, P.; Pineda, B.; Torno, E.; Lluch, A.; Eroles, P. The Antitumor Effect of Metformin Is Mediated by MiR-26a in Breast Cancer. *Int. J. Mol. Sci.* 2016, 17, 1298. [CrossRef] [PubMed]

86. Farhadi, E.; Zaker, F.; Safa, M.; Rezvani, M.R. MiR-101 Sensitizes K562 Cell Line to Imatinib through Jak2 Downregulation and Inhibition of NF-κB Target Genes. *Tumour Biol.* 2016. [CrossRef]

87. Setua, S.; Khan, S.; Yallapu, M.M.; Behrman, S.W.; Sikander, M.; Khan, S.S.; Jaggi, M.; Chauhan, S.C. Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. *J. Gastrointest. Surg.* 2016. [CrossRef] [PubMed]

88. Chen, X.; Zhong, S.-L.; Lu, P.; Wang, D.-D.; Zhou, S.-Y.; Yang, S.-J.; Shen, H.-Y.; Zhang, L.; Zhang, X.-H.; Zhao, J.-H.; et al. MiR-4443 Participates in the Malignancy of Breast Cancer. *PloS ONE* 2016, 11, e0160780. [CrossRef] [PubMed]

89. Fattore, L.; Mancini, R.; Acunzo, M.; Romano, G.; Laganò, A.; Pisanu, M.E.; Malpici, D.; Madonna, G.; Mallardo, D.; Capone, M.; et al. MiR-579-3p Controls Melanoma Progression and Resistance to Target Therapy. *Proc. Natl. Acad. Sci. USA* 2016. [CrossRef]

90. Wang, Y.; Zhao, Y.; Herbst, A.; Kalinski, T.; Qin, J.; Wang, X.; Jiang, Z.; Benedix, F.; Franke, S.; Wartman, T.; et al. MiR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression. *Ann. Surg.* 2016. [CrossRef]

91. Liu, X.; Wang, S.; Yuan, A.; Yuan, X.; Liu, B. MicroRNA-140 Represses Glioma Growth and Metastasis by Directly Targeting ADAM9. *Oncol. Rep.* 2016. [CrossRef]

92. Chen, Y.; Gao, D.-Y.; Huang, L. In Vivo Delivery of MiRNAs for Cancer Therapy: Challenges and Strategies. *Adv. Drug Deliv. Rev.* 2015, 81, 128–141. [CrossRef]

93. Ayers, D.; Nasti, A. Utilisation of Nanoparticle Technology in Cancer Chemoresistance. *J. Drug Deliv.* 2012, 2012, 265691. [CrossRef] [PubMed]

94. Shahari, N.; Mansoori, B.; Davudian, S.; Mohammadi, A.; Baradaran, B. Overcoming the Challenges of SiRNA Delivery: Nanoparticle Strategies. *Curr. Drug Deliv.* 2016, 14, 36–46. [CrossRef]

95. Møller, H.G.; Rasmussen, A.P.; Andersen, H.H.; Johnsen, K.B.; Henriksen, M.; Duroux, M. A Systematic Review of MicroRNA in Glioblastoma Multiforme: Micro-Modulators in the Mesenchymal Mode of Migration and Invasion. *Mol. Neurobiol.* 2013, 47, 131–144. [CrossRef]

96. Broderick, K.E.; Chan, A.; Lin, F.; Shen, X.; Kichaev, G.; Khan, A.S.; Aubin, J.; Zimmermann, T.S.; Sardesai, N.Y. Optimized In Vivo Transfer of Small Interfering RNA Targeting Dermal Tissue Using In Vivo Surface Electroporation. *Adv. Drug Deliv. Rev.* 2008, 60, 685–689. [CrossRef]

97. Chong, R.H.E.; Gonzalez-Gonzalez, E.; Lara, M.F.; Speaker, T.J.; Contag, C.H.; Kaspar, R.L.; Coulman, S.A.; Hargest, R.; Birchall, J.C. Gene Silencing Following SiRNA Delivery to Skin via Coated Steel Microneedles: In Vitro and In Vivo Proof-of-Concept. *J. Control. Release* 2013, 166, 211–219. [CrossRef]

98. Zheng, D.; Giljohann, D.A.; Chen, D.L.; Massich, M.D.; Wang, X.-Q.; Iordanov, H.; Mirkin, C.A.; Paller, A.S. Topical Delivery of SiRNA-Based Spherical Nucleic Acid Nanoparticles for Gene Regulation. *Proc. Natl. Acad. Sci. USA* 2012, 109, 11975–11980. [CrossRef] [PubMed]

99. Haraguchi, T.; Nakano, H.; Tagawa, T.; Ohki, T.; Ueno, Y.; Yoshida, T.; Iba, H. A Potent 2′-O-Methylated RNA-Based MicroRNA Inhibitor with Unique Secondary Structures. *Nucleic Acids Res.* 2012, 40, e58. [CrossRef]

100. Nahar, S.; Kotikam, V.; Kumar, V.A.; Maiti, S. Inhibition of MiR-21 by 3′/5′-Serinyl-Capped 2′-O-Methyl RNA Interspersed with 2′-O-(2-Amino-3-Methoxypyrol) Uridine Units. *Nucleic Acid Ther.* 2016. [CrossRef]

101. Krützfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of MicroRNAs in Vivo with “Antagomirs.” *Nature* 2005, 438, 685–689. [CrossRef]

102. Elmén, J.; Lindow, M.; Silahtaroglu, A.; Bak, M.; Christensen, M.; Lind-Thomsen, A.; Hedtjärn, M.; Hansen, J.B.; Hansen, H.F.; Straarup, E.M.; et al. Antagonism of MicroRNA-122 in Mice by Systemically Administered LNA-AntimiR Leads to up-Regulation of a Large Set of Predicted Target MRNAs in the Liver. *Nucleic Acids Res.* 2008, 36, 1153–1162. [CrossRef]

103. Peacock, H.; Fucini, R.V.; Jayalath, P.; Ibarra-Soza, J.M.; Haringisma, H.J.; Flanagan, W.M.; Willingham, A.; Beal, P.A. Nucleobase and Ribose Modifications Control Immunostimulation by a MicroRNA-122-Mimetic RNA. *J. Am. Chem. Soc.* 2011, 133, 9200–9203. [CrossRef] [PubMed]

104. Huang, A.; Chen, Y.; Wang, X.; Zhao, S.; Su, N.; White, D.W. Functional Silencing of Hepatic Microsomal Glucose-6-Phosphatase Gene Expression in Vivo by Adenovirus-Mediated Delivery of Short Hairpin RNA. *FEBS Lett.* 2004, 558, 69–73. [CrossRef]

105. Ren, G.; Li, T.; Lan, J.Q.; Wilz, A.; Simon, R.P.; Boison, D. Lentiviral RNAi-Induced Downregulation of Adenosine Kinase in Human Mesenchymal Stem Cell Grafts: A Novel Perspective for Seizure Control. *Exp. Neurol.* 2007, 208, 26–37. [CrossRef]

106. Georgiadis, A.; Tschemerhuber, M.; Bainbridge, J.W.B.; Robbie, S.J.; McIntosh, J.; Nathwani, A.C.; Smith, A.J.; Ali, R.R. AAV-Mediated Knockdown of Peripherin-2 in Vivo Using MiRNA-Based Hairpins. *Gene Ther.* 2010, 17, 486–493. [CrossRef] [PubMed]

107. Kota, J.; Chivukula, R.R.; O’Donnell, K.A.; Wentzel, E.A.; Montgomery, C.L.; Hwang, H.-W.; Chang, T.-C.; Vivekanandan, P.; Torbenson, M.; Clark, K.R.; et al. Therapeutic MicroRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model. *Cell* 2009, 137, 1005–1017. [CrossRef] [PubMed]
108. Qiao, C.; Yuan, Z.; Li, J.; He, B.; Zheng, H.; Mayer, C.; Li, J.; Xiao, X. Liver-Specific MicroRNA-122 Target Sequences Incorporated in AAV Vectors Efficiently Inhibits Transgene Expression in the Liver. *Gene Ther.* 2011, 18, 403–410. [CrossRef]

109. Yang, X.; Haurigot, V.; Zhou, S.; Luo, G.; Couto, L.B. Inhibition of Hepatitis C Virus Replication Using Adeno-Associated Virus Vector Delivery of an Exogenous Anti-Hepatitis C Virus MicroRNA Cluster. *Hepatology* 2010, 52, 1877–1887. [CrossRef]

110. Anesti, A.-M. Delivery of RNA Interference to Peripheral Neurons in Vivo Using Herpes Simplex Virus. *Methods Mol. Biol.* 2010, 617, 347–361. [CrossRef]

111. Christensen, M.; Larsen, L.A.; Kauppinen, S.; Schratt, G. Recombinant Adeno-Associated Virus-Mediated MicroRNA Delivery into the Postnatal Mouse Brain Reveals a Role for MiR-134 in Dendritogenesis in Vivo. *Front. Neural Circuits* 2010, 3, 16. [CrossRef] [PubMed]

112. Kasar, S.; Salerno, E.; Yuan, U.; Underbayev, C.; Vollenweider, D.; Laurindo, M.F.; Fernandes, H.; Bonci, D.; Addario, A.; Mazzella, F.; et al. Systemic in Vivo Lentiviral Delivery of MiR-15a/16 Reduces Malignancy in the NZB de Noovo Mouse Model of Chronic Lymphocytic Leukemia. *Genes Immun.* 2012, 13, 109–119. [CrossRef] [PubMed]

113. Miyazaki, Y.; Adachi, H.; Kabuno, M.; Minamiyama, M.; Jiang, Y.-M.; Huang, Z.; Doh, H.; Matsumoto, S.; Kondo, N.; Iida, M.; et al. Viral Delivery of MiR-196a Ameliorates the SMABa Phenotype via the Silencing of CELF2. *Nat. Med.* 2012, 18, 1136–1141. [CrossRef]

114. Pihlmann, M.; Askou, A.L.; Aagaard, L.; Bruun, G.H.; Svalgaard, J.D.; Holm-Nielsen, M.H.; Dagnaes-Hansen, F.; Bek, T.; Mikkelsen, J.G.; Jensen, T.G.; et al. Adeno-Associated Virus-Delivered Polycistronic MicroRNA-Clusters for Knockdown of Vascular Endothelial Growth Factor in J. *Gene Med.* 2012, 14, 328–338. [CrossRef] [PubMed]

115. Majowicz, A.; Maczuga, P.; Kwikkers, K.L.; van der Marel, S.; van Logtenstein, R.; Petry, H.; van Deventer, S.J.; Konstantinova, P.; Ferreira, V. Mir-142-3p Target Sequences Reduce Transgene-Directed Immunogenicity Following Intramuscular Adeno-Associated Virus 1 Vector-Mediated Gene Delivery. *J. Gene Med.* 2013, 15, 219–232. [CrossRef]

116. Lou, W.; Chen, Q.; Ma, L.; Liu, J.; Yang, Z.; Shen, J.; Cui, Y.; Bian, X.-W.; Qian, C. Oncolytic Adenovirus Co-Expressing MiRNA-34a and IL-24 Induces Superior Antitumor Activity in Experimental Tumor Model. *J. Mol. Med.* 2013, 91, 715–725. [CrossRef]

117. Yong, K.L.; Callander, G.E.; Bergin, R.; Samuel, C.S.; Bathgate, R.A.D. Development of Human Cells with RXFP1 Knockdown Using Retroviral Delivery of MicroRNA against Human RXFP1. *Ital. J. Anat. Embryol.* 2013, 118, 10–12.

118. Beavers, K.R.; Werfel, T.A.; Shen, T.; Kavanaugh, T.E.; Kilchrist, K.V.; Mares, J.W.; Fain, J.S.; Wiese, C.B.; Vickers, K.C.; Weiss, S.M.; et al. Magnetic Resonance-Guided Focused Ultrasound Delivery of Temozolomide and Anti-MiR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells. *Int. J. Nanomed.* 2016, 11, 289–299. [CrossRef]

119. Duggal, R.; Zhang, Y.; Subramanian, S.; Price, R.L.; Abounader, R. 370° Magnetic Resonance-Guided Focused Ultrasound Delivery of Polymeric Brain-Penetrating Nanoparticle MicroRNA Conjugates in Glioblastoma. *Virus Research* 2016, 213, 89–98. [CrossRef] [PubMed]

120. Theis, T.; Yao, M.; Park, C.S.; Chen, J.; Kugler, S.; Gibbs, K.M.; Schachner, M. Lentiviral Delivery of MiR-133b Improves Functional Vascular Endothelial Growth Factor in Vivo. *Virus 1 Vector-Mediated Gene Delivery.* 2012, 15, 219–232. [CrossRef]

121. Devulapally, R.; Foygel, K.; Sekar, T.V.; Willmann, J.K.; Paulmurugan, R. Gemcitabine and Antisense-MicroRNA Co-Encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy. *ACS Appl. Mater. Interfaces* 2016, 8, 33412–33422. [CrossRef] [PubMed]

122. Liu, J.-M.; Liang, Z.; Wang, X.; Gu, J.; Yao, Q.; Chen, C. New Polymer of Lactic-Co-Glycolic Acid-Modified Polyethyleneimine for Nucleic Acid Delivery. *Nanomedicine* 2016, 11, 1971–1991. [CrossRef] [PubMed]

123. Liu, Z.; Niu, D.; Zhang, J.; Zhang, W.; Yao, Y.; Li, P.; Gong, J. Amphiphilic Core-Shell Nanoparticles Containing Dense Polyethyleneimine Shells for Efficient Delivery of MicroRNA to Kupffer Cells. *Int. J. Nanomed.* 2016, 11, 2785–2797. [CrossRef]

124. Beavers, K.R.; Werfel, T.A.; Shen, T.; Kavanaugh, T.E.; Kilchrist, K.V.; Mares, J.W.; Fain, J.S.; Wiese, C.B.; Vickers, K.C.; Weiss, S.M.; et al. Porous Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies. *Adv. Mater. Wein.* 2016, 28, 7984–7992. [CrossRef]

125. Vega, R.A.; Zhang, Y.; Curley, C.; Price, R.L.; Abounader, R. 370° Magnetic Resonance-Guided Focused Ultrasound Delivery of Polymeric Brain-Penetrating Nanoparticle MicroRNA Conjugates in Glioblastoma. *Virus Research* 2016, 63 (Suppl. 1), 210. [CrossRef]

126. Bertucci, A.; Prasetyanto, E.A.; Septiadi, D.; Manicardi, A.; Brognara, E.; Gambri, R.; Corradini, R.; De Cola, L. Combined Delivery of Temozolomide and Anti-MiR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells. *Small* 2015, 11, 5687–5695. [CrossRef] [PubMed]

127. Cha, W.; Fan, R.; Miao, Y.; Zhou, Y.; Qin, C.; Shan, X.; Wan, X.; Li, J. Mesoporous Silica Nanoparticles as Carriers for Intracellular Delivery of Nucleic Acids and Subsequent Therapeutic Applications. *Molecules* 2017, 22, 782. [CrossRef]

128. Takaklar, S.; Xu, H.; Chen, J.; Baryekh, K.; Qiu, W.; Zhao, J.X.; Liu, A.G. Gold Nanoparticle Coated Silica Nanorods for Sensitive Visual Detection of MicroRNA on a Lateral Flow Strip Biosensor. * Anal. Sci.* 2016, 32, 617–622. [CrossRef] [PubMed]

129. Tivanan, A.; Orr, W.S.; Gubala, V.; Nooney, R.; Williams, D.E.; McDonagh, C.; Prenter, S.; Harvey, H.; Domingo-Fernández, R.; Bray, L.M.; et al. Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD2 Coated Nanoparticles. *PLoS ONE* 2012, 7, e38129. [CrossRef]

130. Xu, B.; Mao, Z.; Ji, X.; Yao, M.; Chen, M.; Zhang, X.; Hang, B.; Liu, Y.; Tang, W.; Tang, Q.; et al. MiR-98 and Its Host Gene Huwe1 Target Caspase-3 in Silica Nanoparticles-Treated Male Germ Cells. *Sci. Rep.* 2015, 5, 12938. [CrossRef] [PubMed]
157. Nazimek, K.; Bryniarski, K.; Askenase, P.W. Functions of Exosomes and Microbial Extracellular Vesicles in Allergy and Contact and Delayed-Type Hypersensitivity. *Int. Arch. Allergy Immunol.* 2016, 171, 1–26. [CrossRef]

158. Théry, C.; Ostrowski, M.; Segura, E. Membrane Vesicles as Conveyors of Immune Responses. *Nat. Rev. Immunol.* 2009, 9, 581–593. [CrossRef]

159. Cocucci, E.; Racchetti, G.; Meldolesi, J. Shedding Microvesicles: Artefacts No More. *Trends Cell Biol.* 2009, 19, 43–51. [CrossRef]

160. Escrevente, C.; Keller, S.; Altevogt, P.; Costa, J. Interaction and Uptake of Exosomes by Ovarian Cancer Cells. *BMC Cancer* 2011, 11, 108. [CrossRef]

161. Soley, L.; Falank, C.; Reagan, M.R. MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells. *Curr. Osteoporos. Rep.* 2017. [CrossRef] [PubMed]

162. Eisses, J.F.; Chi, Y.; Kaplan, J.H. Stable Plasma Membrane Levels of HCTR1 Mediate Cellular Copper Uptake. *J. Biol. Chem.* 2005, 280, 9635–9639. [CrossRef] [PubMed]

163. Kaplan, J.H.; Maryon, E.B. How Mammalian Cells Acquire Copper: An Essential but Potentially Toxic Metal. *Biophys. J.* 2016, 110, 7–13. [CrossRef] [PubMed]

164. Maryon, E.B.; Molloy, S.A.; Ivy, K.; Yu, H.; Kaplan, J.H. Rate and Regulation of Copper Transport by Human Copper Transporter 1 (HCTR1). *J. Biol. Chem.* 2013, 288, 18035–18046. [CrossRef] [PubMed]

165. Kilari, D.; Iczkowski, K.A.; Pandya, C.; Robin, A.J.; Messing, E.M.; Guancial, E.; Kim, E.S. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-Treated Muscle-Invasive Bladder Cancer Patients. *Anticancer. Res.* 2016, 36, 495–501. [PubMed]

166. Naren, D.; Wu, J.; Gong, Y.; Yan, T.; Wang, K.; Xu, W.; Yang, X.; Shi, F.; Shi, R. Niemann-Pick Disease Type C1(NPC1) Is Involved in Resistance against Imatinib in the Imatinib-Resistant Ph+ Acute Lymphoblastic Leukemia Cell Line SUP-B15/RL. *Leuk. Res.* 2016, 42, 59–67. [CrossRef]

167. Rayner, K.J.; Suárez, Y.; Dávalos, A.; Parathath, S.; Fitzgerald, M.L.; Tamehiro, N.; Fisher, E.A.; Moore, K.J.; Fernández-Hernando, C. MiR-33 Contributes to the Regulation of Cholesterol Homeostasis. *Science* 2010, 328, 1570–1573. [CrossRef] [PubMed]